Analysts Set Expectations for Zoetis’ Q4 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Research analysts at William Blair cut their Q4 2024 earnings per share estimates for shares of Zoetis in a research note issued on Monday, November 4th. William Blair analyst B. Vazquez now expects that the company will post earnings per share of $1.37 for the quarter, down from their prior estimate of $1.44. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. William Blair also issued estimates for Zoetis’ Q2 2025 earnings at $1.67 EPS, Q3 2025 earnings at $1.70 EPS, FY2025 earnings at $6.36 EPS and Q3 2026 earnings at $1.91 EPS.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the business earned $1.36 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year.

A number of other analysts have also issued reports on ZTS. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Up 1.5 %

Shares of ZTS stock opened at $176.83 on Thursday. The company has a market capitalization of $79.78 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 2.61 and a beta of 0.90. The stock’s 50 day simple moving average is $188.15 and its 200 day simple moving average is $179.35. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 3.69. Zoetis has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is presently 32.52%.

Institutional Trading of Zoetis

Several institutional investors have recently bought and sold shares of ZTS. Mizuho Securities USA LLC boosted its stake in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares in the last quarter. Sarasin & Partners LLP boosted its stake in Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock valued at $390,682,000 after buying an additional 1,904,899 shares in the last quarter. Swedbank AB acquired a new stake in Zoetis in the 1st quarter valued at $210,815,000. International Assets Investment Management LLC boosted its stake in Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after buying an additional 937,700 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in Zoetis by 7,608.6% in the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock valued at $144,874,000 after buying an additional 824,843 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.